GlassScriptPhysician profile
Tyler J Pond
NPI 1356844500
$12,777.36
in general payments reported to CMS, 2019-2025
24 companies · $9,007 in 2025
The $9,007 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,156 · 2022: $1,166 · 2023: $804 · 2024: $645 · 2025: $9,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,750 · Food and Beverage: $2,740 · Travel and Lodging: $901 · Education: $64.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,750.00 |
| Food and Beverage | $2,740.05 |
| Travel and Lodging | $900.74 |
| Education | $64.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $8,858.89 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,206.42 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $363.38 | 2021-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $337.14 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $327.36 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $316.82 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $288.91 | 2021-2025 | Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $176.91 | 2021-2025 | Ingrezza |
| Lundbeck LLC | $125.08 | 2021-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $105.54 | 2021-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $104.09 | 2022-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $83.60 | 2021-2024 | Jornay Pm |
| Indivior INC. | $80.10 | 2024-2025 | Sublocade, Perseris |
| Sunovion Pharmaceuticals INC. | $67.70 | 2021-2022 | |
| Corium, LLC | $66.52 | 2022-2025 | Azstarys |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $64.11 | 2025 | |
| Tris Pharma INC | $44.61 | 2021-2022 | |
| Eisai INC. | $36.90 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $36.06 | 2024-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $26.51 | 2021-2022 | |
| Novo Nordisk INC | $15.86 | 2023 | Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.77 | 2024 | Relistor |
| Boston Scientific Corporation | $14.96 | 2025 | General - Pain Management |
| Adlon Therapeutics L.P. | $14.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Pond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.